Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Location
117 Kendrick Street, Suite 450, Needham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 469 % +155%
Debt-to-equity 29.2 %
Return On Equity -29.2 % -101%
Return On Assets -22.6 % +86.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.9M shares +69%
Common Stock, Shares, Outstanding 54.9M shares +70.9%
Entity Public Float 163M USD +478%
Common Stock, Value, Issued 550K USD +70.8%
Weighted Average Number of Shares Outstanding, Basic 54.9M shares +71.5%
Weighted Average Number of Shares Outstanding, Diluted 54.9M shares +71.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.3M USD +11.6%
General and Administrative Expense 16.4M USD +18.7%
Operating Income (Loss) -40.7M USD -14.4%
Nonoperating Income (Expense) 17.9M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -22.8M USD +56.4%
Earnings Per Share, Basic 0 USD/shares +69%
Earnings Per Share, Diluted 0 USD/shares +67.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 87M USD +425%
Assets, Current 90.1M USD +398%
Property, Plant and Equipment, Net 1.36M USD -45%
Operating Lease, Right-of-Use Asset 1.75M USD +185%
Assets 93.6M USD +335%
Accounts Payable, Current 1.12M USD +278%
Employee-related Liabilities, Current 2.57M USD +9.92%
Accrued Liabilities, Current 5.15M USD +12.7%
Liabilities, Current 10.9M USD -28.4%
Operating Lease, Liability, Noncurrent 1.57M USD +183%
Liabilities 13.5M USD -63.4%
Retained Earnings (Accumulated Deficit) -201M USD -12.8%
Stockholders' Equity Attributable to Parent 80.1M USD
Liabilities and Equity 93.6M USD +335%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.62M USD -2.11%
Net Cash Provided by (Used in) Financing Activities -1.87M USD -49%
Net Cash Provided by (Used in) Investing Activities -3K USD +57.1%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 55M shares +70.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.5M USD -8.13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 87.2M USD +418%
Interest Paid, Excluding Capitalized Interest, Operating Activities 252K USD -54.1%
Deferred Tax Assets, Valuation Allowance 52.2M USD +28.7%
Deferred Tax Assets, Gross 52.5M USD +27.8%
Operating Lease, Liability 2.01M USD +81.5%
Depreciation 984K USD +0.31%
Payments to Acquire Property, Plant, and Equipment 3K USD -57.1%
Lessee, Operating Lease, Liability, to be Paid 2.44M USD +107%
Property, Plant and Equipment, Gross 4.79M USD -9.81%
Operating Lease, Liability, Current 437K USD -20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 613K USD +47.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 618K USD +0.82%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 432K USD +492%
Lessee, Operating Lease, Liability, to be Paid, Year Three 628K USD
Deferred Tax Assets, Operating Loss Carryforwards 29.9M USD +29.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 426K USD
Operating Lease, Payments 802K USD +36.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 230K USD +39.4%
Deferred Tax Assets, Net of Valuation Allowance 277K USD -44.7%
Share-based Payment Arrangement, Expense 3.77M USD -24.7%
Interest Expense -3.09M USD -9.59%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%